A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

  • STATUS
    Recruiting
  • End date
    Aug 31, 2022
  • participants needed
    222
  • sponsor
    Seagen Inc.
Updated on 20 April 2021
cancer
measurable disease
hormone therapy
bevacizumab
biomarker analysis
cancer chemotherapy
parp inhibitor
ovarian cancer
fallopian tube
line of therapy
ovarian epithelial cancer
peritoneal cancer
primary peritoneal carcinoma
ovarian epithelial carcinoma
cancer of the ovary
epithelial ovarian cancer
platinum-resistant ovarian cancer

Summary

This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).

Description

The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week cycle (3Q4W) for patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based treatment and determined to be platinum resistant. All patients must have PROC and be eligible for single agent chemotherapy.

The safety run-in period will evaluate the safety of a weekly schedule. The highest dose level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is considered safe and tolerable in the safety run-in period.

Details
Condition Ovarian disorder, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Ovarian Function, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Cancer, ovarian carcinomas, cancer, ovarian, cancer ovarian, cancer of the ovary, fallopian tube cancers, ovarian tumors
Treatment Tisotumab Vedotin
Clinical Study IdentifierNCT03657043
SponsorSeagen Inc.
Last Modified on20 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you female?
Do you have any of these conditions: Fallopian Tube Cancer or Recurrent Ovarian Cancer or Ovarian Cancer or Ovarian Function or Ovarian disorder or Peritoneal Cancer?
Do you have any of these conditions: ovarian tumors or fallopian tube cancers or Peritoneal Cancer or cancer ovarian or Ovarian Cancer or cancer of the ovary or Recurrent Ovarian Cancer o...?
Do you have any of these conditions: cancer of the ovary or fallopian tube cancers or Recurrent Ovarian Cancer or ovarian tumors or cancer, ovarian or ovarian carcinomas or Fallopian Tube...?
Do you have any of these conditions: Peritoneal Cancer or Ovarian disorder or Ovarian Function or Primary Peritoneal Cavity Cancer or Ovarian Cancer or fallopian tube cancers or ovarian t...?
Do you have any of these conditions: Ovarian Cancer or cancer, ovarian or cancer ovarian or ovarian tumors or cancer of the ovary or ovarian carcinomas or Peritoneal Cancer or Fallopian T...?
Do you have any of these conditions: fallopian tube cancers or Ovarian Function or cancer of the ovary or ovarian tumors or Ovarian Cancer or Recurrent Ovarian Cancer or Peritoneal Cancer...?
Do you have any of these conditions: ovarian carcinomas or Ovarian Function or Primary Peritoneal Cavity Cancer or Ovarian disorder or cancer, ovarian or Peritoneal Cancer or ovarian tumo...?
Do you have any of these conditions: Fallopian Tube Cancer or fallopian tube cancers or ovarian tumors or Peritoneal Cancer or Ovarian disorder or Ovarian Cancer or cancer ovarian or Prim...?
Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Safety run-in only: PROC. Patients may have received more than 1 prior systemic treatment regimen in the PROC setting
Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer lines of therapy overall, including at least 1 line of therapy containing bevacizumab or biosimilar
Adjuvant neoadjuvant are considered 1 line of therapy
Patients may have received a PARP inhibitor or an immuno-oncology (IO) agent; any of these regimens are to be considered a line of therapy for the purposes of this study if not used as maintenance therapy
Maintenance therapy (including bevacizumab, PARP inhibitors and IOs) will be considered part of the preceding line of therapy and not to be counted as a new line of therapy
Any chemotherapy regimen change due to toxicity in the absence of disease progression is considered as part of the same line of therapy
Hormonal therapy will be not be counted towards the lines of therapy
Measurable disease according to RECIST v1.1 as assessed by the investigator
An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Life expectancy of at least 3 months
Able to provide fresh or archival tissue for biomarker analysis

Exclusion Criteria

Primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
Patients with clinical symptoms or signs of gastrointestinal obstruction with the past 6 months or who currently require parenteral nutrition
Hematological: Known past or current coagulation defects leading to an increased risk of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis, ongoing major bleeding, or trauma with increased risk of life-threatening bleeding within 8 weeks of trial entry
Cardiovascular: Clinically significant cardiac disease including uncontrolled hypertension, unstable angina, acute myocardial infarction with 6 months of screening, serious cardiac arrhythmia requiring medication, medical history of congestive heart failure, or medical history of decreased cardiac ejection fraction of <45%
Ophthalmological: Active ocular surface disease at baseline or prior episode of cicatricial conjunctivitis or Stevens Johnson syndrome
Prior treatment with MMAE-derived drugs
Inflammatory bowel disease including Crohn's disease and ulcerative colitis
Ongoing, acute, or chronic inflammatory skin disease
Uncontrolled tumor-related pain
Inflammatory lung disease requiring chronic medical therapy
Grade 3 or higher pulmonary disease unrelated to underlying malignancy
Uncontrolled pleural or pericardial effusions
Grade >1 peripheral neuropathy
Patients who are pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note